Features of C-reactive protein in COVID-19 patients with different ages, clinical types and outcomes: a cohort study

  1. Gaojing Qu
  2. Guoxin Huang
  3. Meiling Zhang
  4. Hui Yu
  5. Xiaoming Song
  6. Haoming Zhu
  7. Lei Chen
  8. Yunfu Wang
  9. Bin Pei

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

Background

To characterize C-reactive protein (CRP) changes features from patients with coronavirus disease 2019 (COVID-19) and to quantify the correlation between CRP value and clinical classification.

Methods

This was a bidirectional observational cohort study. All laboratory confirmed COVID-19 patients hospitalized in Xiangyang No.1 People’s Hospital were included. Patients’ general information, clinical type, CRP value and outcome were collected. Patients were grouped according to the age, clinical type and outcome, and their CRP were compared. The CRP value, age gender, and clinical type were used to build a categorical regression model to investigate the association between CRP and clinical type.

Results

The 131 patients aged 50.13±17.13 years old. There were 4 mild, 88 moderate, 21 severe and 18 critical cases. Statistical significance of CRP median exists between different clinical types and ages. There were 10 deaths and 121 cases have been discharged. The CRP in death group dramatically increased continuously until died, while increased firstly and decreased later in the survivor and survivor in critical type. The categorical regression model also showed that CRP and age had significant coefficient. During the first 15 days from symptom onset, the maximum of CRP ranged between 0.47-53.37 mg/L were related to mild combined with moderate type, ranged 53.84-107.08 mg/L were related to severe type, and 107.42-150.00 mg/L were related to the critical type.

Conclusions

CRP showed different distribution feature and existed differences in various ages, clinical types and outcomes of COVID-19 patients. The features corresponded with disease progression.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2020.10.26.20220160: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: The study was approved by the ethics review board of Xiangyang No.1 People’s Hospital (No. 2020GCP012) and registered at the Chinese Clinical Trial Registry as ChiCTR2000031088.
    Consent: Informed consent from patients has been exempted since this study is an observational cohort study that neither involve patients’ personal privacy nor incur greater than the minimal risk.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    The reagent was C-reactive protein test kit (Abbott Laboratories), the test instrument is automatic biochemical immunoassay analyzer (Abbott Laboratories ARCHITECT c16200), the normal range of CRP value was 0-8 mg/L.
    Abbott
    suggested: (Abbott, RRID:SCR_010477)
    Abbott Laboratories
    suggested: None
    Statistical analysis: All statistical analyses were performed using SPSS 20.0 Binary data were described using frequency and percentage.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)
    All graphs were processed using GraphPad Prism 8.0 and Photoshop CC 14.2 software.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)
    Photoshop
    suggested: (Adobe Photoshop, RRID:SCR_014199)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2020.10.26.20220160 on medRxiv